Article révisé par les pairs
Titre:
  • Comment by European Alzheimer’s Disease Consortium (EADC) investigators on the negative recommendation of the CHMP on the marketing authorization of donanemab for early Alzheimer’ s disease
Auteur:Jessen, Frank; Arbizu, Javier; Boada, Mercé; Balasa, Mircea; Bennys, Karim; Boban, Marina; Bürger, Katharina; Chincarini, Andrea; Cagnin, Annachiara; De Deyn, Peter Paul; Düzel, Emrah; Engelborghs, Sebastiaan; Ewers, Michael; Exalto, Lieza; van der Flier, Wiesje; Fortea, Juan; Frederiksen, Kristian Steen; Frisoni, Giovanni G.B.; Frölich, Lutz; Garza-Martinez, Alejandro; Grimmer, Timo; Hanseeuw, Bernard; Hort, Jakub; Ivanoiu, Adrian; Kehoe, Patrick; Kennelly, Sean P; Kern, Silke; Klöppel, Stefan; Krajčovičová, Lenka; Kramberger, Milica; McGuinness, Bernadette; Mecocci, Patrizia; Oberstein, Timo Jan; Ousset, Pierre-Jean; Paquet, Claire; Perneczky, Robert; Piazza, Fabrizio; Plantone, Domenico; Rainero, Innocenzo; Sacco, Guillaume; Salmon, Eric; Santana, Isabel; Scarmeas, Nikolaos; Schneider, Anja; Schott, Jonathan M; Solje, Eino; Stefanova, Elka; Stögmann, Elisabeth; Strauss, Mélanie; Sutovsky, Stanislav; Waldemar, Gunhild; Winblad, Bengt
Informations sur la publication:The Journal of Prevention of Alzheimer's Disease, 12, 8, page (100259)
Statut de publication:Publié, 2025-09-01
Sujet CREF:Sciences bio-médicales et agricoles
Langue:Anglais
Identificateurs:urn:issn:2274-5807
info:doi/10.1016/j.tjpad.2025.100259
info:pii/S227458072500202X

Documents en relation

DI-fusion